ScienceDaily (May 29, 2009) — A new blood test used in combination with a conventional prostate-specific antigen (PSA) screening sharply increases the accuracy of prostate cancer diagnosis, and could eliminate tens of thousands of unneeded, painful, and costly prostate biopsies annually, according to a study led by researchers at Dana-Farber Cancer Institute.
At the annual meeting of the American Society of Clinical Oncology in Orlando, Fla., William K. Oh, M.D., and Robert W. Ross, M.D., will report that the six-gene molecular diagnostic test, when combined with a PSA test, accurately detected prostate cancer more than 90 percent of the time. Earlier studies suggest that the conventional PSA test is 60-70 percent accurate in detecting cancer. The findings will be discussed at a poster session on May 31.
Men who are found to have elevated levels of PSA in routine screening tests are often referred for a biopsy of the gland to check for tumors. Nearly two-thirds of biopsies performed — a painful procedure with some risk of complications — do not find any cancerous cells. This high rate of “false positive” PSA test results underscores the need for a more accurate method for detecting prostate cancer, said Oh, who is the clinical director of the Lank Center for Genitourinary Oncology at Dana-Farber.
The two-year study involved 484 participants. The group comprised 204 men with known prostate cancer, 110 men with benign prostatic hypertrophy (BPH), and 170 healthy men in a control group. (BPH can elevate PSA levels in the blood, which often leads to a biopsy to rule out prostate cancer.) These groups were split into age-matched training and validation sets.
The researchers sought to measure the accuracy of a six-gene whole blood RNA transcript-based diagnostic test developed by Source MDx in Boulder, Colo., both in terms of its sensitivity (the ability to detect prostate cancer) and specificity (the ability to identify people who don’t have prostate cancer).
Source MDx researchers developed the test after initially working with a set of 174 candidate genes whose activity was compared in the different study groups. They narrowed the pool down to just six genes that, as a group, were highly sensitive in predicting which patients had prostate cancer and which were normal.
The study found that “the six-gene model was more accurate than PSA alone at predicting cancer if you had it and no cancer if you didn’t,” said Oh. The test’s accuracy improved even more when PSA measurements were added. Combined, the two tests achieved a diagnostic accuracy of more than 90 percent in specificity and sensitivity and eliminated most of the false-positives yielded by the PSA test.
Based on these findings, the researchers are planning to conduct a larger, multicenter clinical trial involving approximately 1,000 men to determine if the findings remain valid.
“These findings are very encouraging and suggest that this new test could spare tens of thousands of men from undergoing an unnecessary biopsy,” Oh said. “However, until we can verify our findings, it is important to recognize that the PSA test, despite its limitations, is still the best test available for diagnosing prostate cancer at this time.”
The study was funded in part by Source MDx and a Prostate Cancer SPORE grant at Dana-Farber/Harvard Cancer Center.
29000 Men Comment
This is really good news. A great deal of the current controversy over the value of PSA testing revolves around the false-positive issue. Anything that increases the probability of an accurate test outcome will be a welcome improvement. Until these tests are commonplace, however, the PSA remains the best available tool. A Free PSA test combined with a PSA test (which is total PSA) provides even more predictive power to the PSA test (visit http://www.prostatecancerawarenessproject.org, “early detection” tab, for a brief definition of the Free PSA test). I believe it is unfortunate that writers continue to focus on the “pain” associated with a biopsy. While men have different pain thresholds, my diagnosis required two separate needle biopsy sessions with 18 cores each, and I did not find either one particularly uncomfortable. According the American Cancer Society, fully 49% of men do not test annually for prostate cancer and much of this could be due to this focus on the “pain” of the DRE and the needle biopsy. Almost 29,000 men each year in the United States from prostate cancer. Wouldn’t it really be a shame if they are the ones that do not test because of this “pain” focus?